FindTrial
Sign In

Effect of insulin therapy on plasma levels of igf-1 markers in type 2 diabetic patients

Effect of insulin therapy on plasma levels of igf-1 markers in type 2 diabetic patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026015
Enrollment
Unknown
Registered
2019-09-18
Start date
2019-09-17
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

control group:Oral Antidiabetic Drug
experimental group:Subcutaneous injection of insulin

Sponsors

Tianjin Xiqing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed type 2 diabetes; 2. Aged >= 20 years, gender no limitation; 3. Single drug metformin treatment after glycosylated hemoglobin (HbA1c) >7.0%.

Exclusion criteria

Exclusion criteria: 1. Pregnant women, pregnant or lactating women and patients with gestational diabetes mellitus; 2. Suffering from acute complications of diabetes or infections and other stress conditions; 3. Combine all kinds of serious cardiovascular and cerebrovascular diseases leading to life can not take care of themselves; 4. Patients with other obvious complications, such as: glomerular filtration rate less than 60 ml or liver disease (elevated ALT or AST is 3 times higher than the normal upper limit); 5. Also suffering from other endocrine disorders, such as hyperthyroidism, cortisol hypertrophy; 6. Patients with cancer who are receiving radiotherapy and chemotherapy.

Design outcomes

Primary

MeasureTime frame
IGF-1;IGF-BP3;—

Countries

China

Contacts

Public ContactShuying Li

Tianjin Xiqing Hospital

lsy_tj2006@163.com+86 15122683073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026